ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,721 to 2,740 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Video-based Intervention vs Usual Care: Number of Participants That Initiate an Osteoporosis Prescription Medication157 of 1,342

153 of 1,342

0.3 points

-2.1 to 2.7

2,684NCT01907269

A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care

Transdisciplinary Approach vs Multidisciplinary Approach: Behavioral Symptoms143 of 788

334 of 1,889

0.5 points

-2.6 to 3.8

2,677NCT03442322

Optimizing Care for Patients With Dementia

Transdisciplinary Approach vs Multidisciplinary Approach: Rejection of Care131 of 788

302 of 1,889

0.6 points

-2.3 to 3.8

2,677NCT03442322

Optimizing Care for Patients With Dementia

Transdisciplinary Approach vs Multidisciplinary Approach: Wandering88 of 788

117 of 1,889

5.0 points

2.6 to 7.6

2,677NCT03442322

Optimizing Care for Patients With Dementia

Transdisciplinary Approach vs Multidisciplinary Approach: Physical Restraints Use3 of 786

102 of 1,887

-5.0 points

-6.2 to -3.8

2,673NCT03442322

Optimizing Care for Patients With Dementia

Arm I:Sentinel Node Resection+Conventional Axillary Dissection vs Arm II: Sentinel Node Resection Followed by Node Examination: Morbidity - Number of Participants With Residual Arm Tingling175 of 1,329

90 of 1,343

6.5 points

4.2 to 8.7

2,672NCT00003830

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Cilostazol vs Aspirin: Number of Patients With First Recurrence of Cerebral Infarction72 of 1,337

88 of 1,335

-1.2 points

-3.0 to 0.6

2,672NCT00234065

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cilostazol vs Aspirin: Number of Patients With First Occurrence of Haemorrhagic Event23 of 1,337

57 of 1,335

-2.5 points

-3.9 to -1.3

2,672NCT00234065

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cilostazol vs Aspirin: Numbers of Patients With First Occurence of Stroke82 of 1,337

119 of 1,335

-2.8 points

-4.8 to -0.8

2,672NCT00234065

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cilostazol vs Aspirin: Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease86 of 1,337

103 of 1,335

-1.3 points

-3.2 to 0.7

2,672NCT00234065

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cilostazol vs Aspirin: Number of Deaths From Any Cause13 of 1,337

13 of 1,335

-0.0 points

-0.8 to 0.8

2,672NCT00234065

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cilostazol vs Aspirin: Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events138 of 1,337

186 of 1,335

-3.6 points

-6.1 to -1.1

2,672NCT00234065

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cilostazol vs Aspirin: serious adverse events372 of 1,337

433 of 1,335

-4.6 points

-8.1 to -1.1

2,672NCT00234065

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Transdisciplinary Approach vs Multidisciplinary Approach: Falls326 of 785

750 of 1,887

1.8 points

-2.3 to 5.9

2,672NCT03442322

Optimizing Care for Patients With Dementia

HIV Self-testing vs Information Only: Newly Identified HIV Infections25 of 1,325

11 of 1,340

1.1 points

0.2 to 2.0

2,665NCT02067039

Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)

Transdisciplinary Approach vs Multidisciplinary Approach: Unintended Weight Loss125 of 781

302 of 1,884

-0.0 points

-3.0 to 3.1

2,665NCT03442322

Optimizing Care for Patients With Dementia

Oxaliplatin + Leucovorin + 5-Fluorouracil vs Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab: serious adverse events81 of 1,326

270 of 1,334

-14.1 points

-16.7 to -11.6

2,660NCT00096278

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Immediate Monitoring vs Delayed Monitoring: Incidence of Newly Diagnosed AF in the Immediate vs Delayed Monitoring Group53 of 1,366

12 of 1,293

3.0 points

1.8 to 4.2

2,659NCT02506244

mHealth Screening to Prevent Strokes

NanoFlu vs Fluzone Quadrivalent: deaths from any cause8 of 1,333

8 of 1,319

-0.0 points

-0.7 to 0.6

2,652NCT04120194

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

NanoFlu vs Fluzone Quadrivalent: serious adverse events136 of 1,333

125 of 1,319

0.7 points

-1.5 to 3.0

2,652NCT04120194

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=137"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=137

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01907269-d287b278",
        "title": "Video-based Intervention vs Usual Care: Number of Participants That Initiate an Osteoporosis Prescription Medication",
        "summary": "157 of 1342 against 153 of 1342; risk difference 0.3 points, 95% interval -2.1 to 2.7; NCT01907269, A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care",
        "record": "/library/comparisons/NCT01907269-d287b278",
        "nct_id": "NCT01907269",
        "kind": "outcome",
        "participants": 2684,
        "risk_difference": {
          "value": 0.002980625931445602,
          "lower": -0.021265352642068185,
          "upper": 0.027231853512111368
        },
        "group_1": "157 of 1,342",
        "group_2": "153 of 1,342",
        "difference": "0.3 points",
        "interval": "-2.1 to 2.7",
        "trial_title": "A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care"
      },
      {
        "id": "NCT03442322-503daa11",
        "title": "Transdisciplinary Approach vs Multidisciplinary Approach: Behavioral Symptoms",
        "summary": "143 of 788 against 334 of 1889; risk difference 0.5 points, 95% interval -2.6 to 3.8; NCT03442322, Optimizing Care for Patients With Dementia",
        "record": "/library/comparisons/NCT03442322-503daa11",
        "nct_id": "NCT03442322",
        "kind": "outcome",
        "participants": 2677,
        "risk_difference": {
          "value": 0.004658952578782294,
          "lower": -0.02634263735014975,
          "upper": 0.03755539202981919
        },
        "group_1": "143 of 788",
        "group_2": "334 of 1,889",
        "difference": "0.5 points",
        "interval": "-2.6 to 3.8",
        "trial_title": "Optimizing Care for Patients With Dementia"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=138",
  "request_id": "WiDkBrMG8PbCQdgE"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?